Cite
MLA Citation
James Clerkin et al.. “TMOD-12. ESTABLISHING A CLINICALLY RELEVANT MODEL OF MESENCHYMAL GLIOBLASTOMA (GBM) TO STUDY RESPONSE TO STANDARD OF CARE TREATMENT AND IMMUNE CHECKPOINT INHIBITION (ICI)..” Neuro-oncology, vol. 22, n.d., p. ii230. http://access.bl.uk/ark:/81055/vdc_100117808432.0x000008